Ananda Developments Appoints Professor Marie Fallon to Scientific Advisory Board
Key Insights
Ananda Developments (search) has appointed Professor Marie Fallon to its Scientific Advisory Board (SAB) to enhance its research and clinical development of CBD-based therapies.
Professor Fallon, an expert in palliative medicine and neuropathy (search), will provide technical advice and guidance to Ananda's scientific activities.
She is the lead investigator for Ananda's Phase II study on MRX1 for Chemotherapy Induced Peripheral Neuropathy (search), bringing valuable expertise to the trial.
Ananda Developments (search) plc has announced the appointment of Professor Marie Fallon to its Scientific Advisory Board (SAB). This strategic move aims to bolster the company's research and clinical development efforts in CBD-based therapies for complex inflammatory pain conditions.
Professor Fallon, a distinguished figure in palliative medicine, will provide expert technical advice and guidance to Ananda. Her appointment is expected to significantly enhance the company's ability to navigate the complexities of drug development and clinical trials.
Professor Marie Fallon's Expertise
Professor Fallon is a Professor of Palliative Medicine at the University of Edinburgh and an Honorary Consultant in Palliative Medicine at the Edinburgh Cancer Centre. With extensive experience in pain and cachexia research in cancer patients, she has played a pivotal role in developing international palliative care guidelines, including those for ESMO and ASCO.
Notably, Professor Fallon is the lead investigator for Ananda's Phase II study evaluating the pain-relieving effects of MRX1 in patients with Chemotherapy Induced Peripheral Neuropathy (search) (CIPN). Her involvement underscores the company's commitment to addressing this challenging condition.
Role of the Scientific Advisory Board
The SAB, chaired by Professor Clive Page, a non-executive director of Ananda Developments (search) plc, convened its first meeting in Edinburgh in May 2024. The board's primary objectives include:
- Reviewing and validating Ananda's scientific activities.
- Providing strategic advice and identifying unmet medical needs suitable for Ananda's drug candidates.
- Guiding clinical trial and protocol development.
- Reviewing publications from company projects.
- Advising on regulatory pathways to achieve Marketing Authorisation for drug candidates.
Leadership Perspective
Ananda CEO, Melissa Sturgess, expressed enthusiasm about Professor Fallon's appointment, stating, "We are delighted and honoured to have Professor Fallon join our SAB. She is a Key Opinion Leader in neuropathy (search) and has conducted previous research using cannabinoids. Her contribution to our drug development work is invaluable and her expertise will be instrumental in ensuring the success of our future research and clinical development programmes."
About Ananda Developments
Ananda Developments (search) is focused on developing cannabinoid-based medicines for treating complex, chronic inflammatory pain conditions. The company is listed on the AQSE exchange.